Loading clinical trials...

Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGEARLY Phase 1NCT06119490

Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis

Lead sponsor: Peng Zhang•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Chao Ji

CONTACT

+86 18651619908 jichaofy@fjmu.edu.cn

Peng Zhang

CONTACT

+86 13645096437 396159837@qq.com

Related studies

RECRUITINGPhase 1/2

LYell SYndrome MEsenchymal Stromal Cells Treatment

NCT04711200 · Epidermal Necrolysis, Lyell Syndrome, and more

COMPLETEDNA

Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN

NCT06474078 · Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis

WITHDRAWNPhase 1/2

Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis

NCT02319616 · Toxic Epidermal Necrolysis

UNKNOWN

Severe Cutaneous Adverse Reactions in Thailand

NCT02574988 · Steven-Johnson Syndrome, Toxic Epidermal Necrolysis, and more

WITHDRAWNPhase 2

Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)

NCT00372723 · Toxic Epidermal Necrolysis

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 28, 2023Terms

Trial snapshot

StatusRECRUITING

PhaseEARLY_PHASE1

Enrollment30

Start dateJul 2023

Last updatedNov 28, 2023

Condition

Toxic Epidermal Necrolysis

Locations shown

Department of Dermatology, the First Affiliated Hospital of Fujian Medical University.

Fuzhou, Fujian

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 28, 2023Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions